Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2023 | Advancing targeted therapies for SCLC

Sophie Cousin, MD, Institut Bergonié, Bordeaux, France, discusses the field of targeted therapies for small cell lung cancer (SCLC) and the latest targets under evaluation for SCLC. The field of targeted therapies for SCLC is still limited. Previous treatments targeting DLL3 showed toxicity and limited overall response rates. However, there is hope that new drugs may provide safer and more effective treatment options by targeting DLL3 in specific subgroups of the SCLC population. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.